| ADMA Biologics is a commercial biopharmaceutical company. Co.'s products include: BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI), also known as Primary Immunodeficiency Disease; ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an IVIG product indicated for the treatment of PI; and Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. Co.'s products and product candidates are intended to be used by physician personnel. We show 30 historical shares outstanding datapoints in our coverage of ADMA's shares outstanding history.|
Understanding the changing numbers of ADMA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMA by allowing them to research ADMA shares outstanding history
as well as any other stock in our coverage universe.